Your browser doesn't support javascript.
loading
Rivaroxaban: A novel anticoagulant.
Indian J Med Sci ; 2010 Nov; 64(11) 520-528
Article in En | IMSEAR | ID: sea-145574
ABSTRACT
For more than 50 years, warfarin has single-handedly ruled the world of anti-coagulation without any competition, whatsoever! The anticoagulant was made available in 1940 and since then no other anti-coagulant has ever been able to match it in the clinical arena. But it looks like that the advances in the field of anti-coagulation, for the first time, have seriously started to erode its base. This review takes a look at rivaroxaban, a direct factor Xa inhibitor and one of the most foremost competitors of warfarin.
Subject(s)
Key words
Full text: 1 Index: IMSEAR Main subject: Thiophenes / Blood Coagulation / Humans / Biological Availability / Cardiovascular Diseases / Factor Xa / Morpholines / Outcome Assessment, Health Care / Drug Monitoring / Pharmacovigilance Language: En Journal: Indian J Med Sci Year: 2010 Type: Article
Full text: 1 Index: IMSEAR Main subject: Thiophenes / Blood Coagulation / Humans / Biological Availability / Cardiovascular Diseases / Factor Xa / Morpholines / Outcome Assessment, Health Care / Drug Monitoring / Pharmacovigilance Language: En Journal: Indian J Med Sci Year: 2010 Type: Article